^
Association details:
| Biomarker: | KMT2D mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Epidaza (chidamide) (PI3K inhibitor, AKT inhibitor, HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor, MAPK inhibitor, HDAC10 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma
Published date:
10/23/2020
Excerpt:
This study aimed to evaluate efficacy and safety of oral HDACI tucidinostat (formerly known as chidamide) plus R-CHOP (CR-CHOP) in elderly patients with newly diagnosed DLBCL...mutations in KMT2D, but not in CREBBP/EP300, were associated with inferior PFS and OS (P = 0.043 and < 0.001, respectively, Fig. 4b). The 2-year PFS and OS rates were 40% (95% CI 5–75) and 40% (95% CI 5–75) in patients with KMT2D mutation, significantly shorter than those without mutation (68% [95% CI 47–82] and 89% [95% CI 70–96]).
Secondary therapy:
R-CHOP
DOI:
10.1186/s13148-020-00948-9
Trial ID:
